Downstream GPCR inhibition

Abstract

The article provides the highlights on cancer research, which is an alternative approach to block GPCR-mediated signalling. They developed a novel anticancer agent, that selectively inhibits the heterotrimeric G-protein subunit complex. The authors reportedly identified the lead compound BIM-46174, and tested its antiproliferative effects by using xenograft models. This study also shows that a heterotrimeric G-protein can be used treat aggressive human cancers.